for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Abrysvo now offers the broadest ...
Progress in targeted signaling inhibition and immunotherapy has spurred a race to transform treatment across virtually all cancer disease sites. There is ample preclinical data pointing toward the ...